Abstract
Acute promyelocytic leukemia（APL）, a distinct subtype of acute myeloid leukemia, often presents with severe bleeding as its initial manifestation, posing a significant diagnostic and therapeutic challenge because of its aggressive onset. Although the 5-year disease-free survival rate for APL now exceeds 90%, substantial hurdles remain in optimizing the diagnostic and treatment protocols for pediatric APL. To improve the overall standard of care and address these challenges, the Chinese diagnosis and treatment guideline for pediatric APL grounded in robust evidence-based medical research was developed.